Search

Displaying results 6161 - 6170 of 10000 in total
  1. Drug

    MLN2704

    go.drugbank.com/drugs/DB06513
    Investigational

    A Phase 1/2 trial (NCT00070837) evaluated the safety, dosage, and pharmacokinetics of MLN2704 in patients with metastatic androgen-independent prostate cancer.

  2. Drug

    Farletuzumab

    go.drugbank.com/drugs/DB05595
    Investigational

    Farletuzumab (MORAb-003) is a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancer.

  3. Drug

    Gemcabene

    go.drugbank.com/drugs/DB05123
    Investigational

    Gemcabene is a new drug that lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C).

  4. Drug

    Nafithromycin

    go.drugbank.com/drugs/DB16246
    Investigational

    Nafithromycin is under investigation in clinical trial NCT02903836 (Phase II Study of Oral Nafithromycin in CABP).

  5. Drug

    Gambir

    go.drugbank.com/drugs/DB14298
    Investigational

    Gambir is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  6. Drug

    Pomegranate

    go.drugbank.com/drugs/DB14317
    Investigational

    Pomegranate is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  7. Drug

    Mesoheme

    go.drugbank.com/drugs/DB02577
    Experimental

    It is found free in tissues and as the prosthetic group in many hemeproteins.

  8. Drug

    Preimplantation factor

    go.drugbank.com/drugs/DB16301
    Investigational

    Preimplantation factor is under investigation in clinical trial NCT03593460 (Phase II Autoimmune Hepatitis).

  9. Drug

    LCP-AtorFen

    go.drugbank.com/drugs/DB05769
    Investigational

    LCP-AtorFen is a fixed-dose combination therapy for the treatment of high cholesterol levels combining atorvastatin (the active ingredient of Lipitor®) and the lowest dose of fenofibrate without food effect … LCP-AtorFen is designed to be a once daily tablet offering a powerful and safe treatment of high cholesterol levels, addressing three primary cardiovascular risk factors: low density lipoprotein cholesterol

  10. Drug

    Ciglitazone

    go.drugbank.com/drugs/DB09201
    Experimental

    Ciglitazone is a potent and selective PPARγ ligand with an EC50 of 3.0 µM. It is also an anti-hyperglycemic agent in the ob/ob murine model in vivo. … Developed by Takeda Pharmaceuticals in the early 1980s, it is considered the prototypical compound for the thiazolidinedione class.